The situation surrounding Valeant Pharmaceuticals has transformed the company into a "great mystery," CNBC's Jim Cramer said Monday. "The numbers...
Read moreOptions expert Pete Najarian joined CNBC Pro for an exclusive Q&A to share his approach to investing. Najarian, who was...
Read moreJustin Sullivan | Getty Images The CAT logo is displayed on Caterpillar construction equipment. Caterpillar on Thursday cut its first-quarter...
Read moreApple stock has been floundering for the past 11 months, falling nearly 22 percent since its high of $134.54 in...
Read moreShares of Valeant Pharmaceuticals tumbled on Tuesday after the company cut its 2016 revenue forecast by about 12 percent and...
Read moreOne look at the action on Valeant's stock on Tuesday, and now investors understand why Jim Cramer preaches that when...
Read moreIn recent years, North Dakota's Bakken formation was synonymous with boom times. Crude production grew 10 times over, unemployment fell...
Read moreIt was one month ago—Feb 11—that the market bottomed. One factor was likely JPMorgan CEO Jamie Dimon's announcement that day...
Read moreThe stock market is looking wobbly. Bonds are paying you about what you're losing to inflation. And the rest of...
Read moreEveryone by now is well aware that IT networks are subject to various cyber threats, and small and medium size...
Read more